

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



李 氏 大 藥 廠

Lee's Pharmaceutical Holdings Limited

李 氏 大 藥 廠 控 股 有 限 公 司 *

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

CLARIFICATION ANNOUNCEMENT TO PRESS ARTICLE

The board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”) is aware of a press article (the “**Press Article**”) which appears today in the newspaper “am730” and website of “am730” relating to the Company’s “prospective launch of a new medicine at the end of next year with a target sales revenue of up to HK\$300 million”.

In respect of the Press Article, the Board would clarify as follows:

As disclosed in the annual report for the year ended 31 December 2010 made by the Company on 21 March 2011, the Company is cooperating with a pharmaceutical company in the United States in developing a new medicine for pulmonary hypertension patients (the “**New Medicine**”). It is a very initial intention of the Company to launch the New Medicine in the market in mainland China in the future but the Company has not yet scheduled any definite launch date for the New Medicine, and therefore the New Medicine may or may not be launched at the end of next year.

Further, the Board would stress that the estimation of the annual sales revenue of the New Medicine of up to HK\$300 million is only a preliminary estimation made by the Company and it may not be accurate. The actual annual sales revenue of the New Medicine, if launched, could be much lower. Further, such estimation only refers to the estimated annual sales revenue of the New Medicine to be generated at a few years after the formal launch of the New Medicine, the date of which is also not scheduled as at the date of this Announcement. The figures are not representing any target sale amount on the New Medicine.

In addition, the period covered for the increase in sale of drug for reduction of bleeding (i.e. Slounase®) and drug for the treatment of cardiovascular diseases (i.e. Carnitene®) (i.e. in the first half of this year) is not accurately reported. The increase in sale of drug for the reduction of bleeding and drug for the treatment of cardiovascular diseases were 77% and 60% respectively in the first quarter of this year. The information on the increase in sale of the aforesaid medicines has been disclosed in the first quarterly report made by the Company on 23 May 2011.

Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 18 July 2011

** For identification purpose only*

As at the date thereof, Ms. Lee Siu Fong (Chairman of the Company), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors; Mr. Mauro Bove is non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.